NYSE
BDXA

Becton, Dickinson and Company

Prices are adjusted according to historical splits.

Becton, Dickinson and Company Stock Price

Vitals

Today's Low:
$58.9150
Today's High:
$62.3200
Open Price:
$60.7600
52W Low:
$49.07
52W High:
$68.35
Prev. Close:
$60.6000
Volume:
6151137

Company Statistics

Market Cap.:
$65.347 billion
Book Value:
78.263
Revenue TTM:
$0.000 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
0%
Return on Equity TTM:
0%

Company Profile

Becton, Dickinson and Company had its IPO on 2017-05-11 under the ticker symbol BDXA.

The company operates in the sector and industry. Becton, Dickinson and Company has a staff strength of 76,032 employees.

Stock update

Shares of Becton, Dickinson and Company opened at $60.76 at the start of the last trading session i.e. 2020-04-30.

The stocks traded within a range of $58.92 - $62.32, and closed at $59.24.

This is a -2.24% slip from the previous day's closing price.

A total volume of 6,151,137 shares were traded at the close of the day’s session.

In the last one week, shares of Becton, Dickinson and Company have slipped by -5.97%.

Becton, Dickinson and Company's Key Ratios

Becton, Dickinson and Company has a market cap of $65.347 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Becton, Dickinson and Company’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $4.755 billion. The EBITDA ratio measures Becton, Dickinson and Company's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Becton, Dickinson and Company’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.

In Q0.33333333333333, Becton, Dickinson and Company’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Becton, Dickinson and Company’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Becton, Dickinson and Company’s profitability.

Becton, Dickinson and Company stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Becton, Dickinson and Company stock pays annual dividends of $3.06 per share, indicating a yield of 5.06% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Becton, Dickinson and Company ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Becton, Dickinson and Company ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Becton, Dickinson and Company’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Becton, Dickinson and Company's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Becton, Dickinson and Company paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$59.24
52-Week High
$68.35
52-Week Low
$49.07
Analyst Target Price
$None

Becton, Dickinson and Company stock is currently trading at $59.24 per share. It touched a 52-week high of $68.35 and a 52-week low of $68.35. Analysts tracking the stock have a 12-month average target price of $None.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Becton, Dickinson and Company

The stock symbol (also called stock or share ticker) of Becton, Dickinson and Company is BDXA

The IPO of Becton, Dickinson and Company took place on 2017-05-11

Similar Industry Stocks ()

Last Price
Chg
Chg%
$39.25
-0.53
-1.33%
$27.39
-0.61
-2.18%
JFrog Ltd (FROG)
$22.99
-1.76
-7.11%
$32.83
-0.62
-1.85%
$2
-0.13
-6.1%
$20.19
-0.54
-2.6%
$123.78
-2.79
-2.2%
$37.07
-0.59
-1.57%
$11.81
-0.17
-1.42%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company’s BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits, reagent systems, bench-side solutions, and molecular indexing and next-generation sequencing sample preparation products, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company’s BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, thoracic and abdominal drainage, and surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Address

None